Esmark Inc. Announces All-Cash Public Offer for U.S. Steel Shares
14.8.2023 21:54:00 EEST | Business Wire | Press release
Esmark, Inc. announced today a voluntary public cash and exchange offer for all issued and outstanding shares in U.S. Steel Corporation (NYSE: X) (“U.S. Steel”) for $35 USD per share. The initial offer period runs from August 14, 2023, to November 30, 2023, and may be extended. Completion of the Offer is expected in Q4 2023, subject to regulatory and antitrust clearances.
“With more than 40 years of steel industry experience, and as a former executive and statutory representative of U.S. Steel, I have significant intimacy with the steel business in the U.S. and around the globe,” said James P. Bouchard, Chairman & CEO of Esmark, Inc., Executive Committee Member of the American Steel Institute and the European Steel Association (Eurofer). Bouchard is Forever Chairman & CEO of Esmark/Wheeling Pittsburg Steel (Ticker Symbol: ESMK). Under Bouchard’s helm, Esmark/Wheeling Pittsburg was the fourth largest steel company in the U.S.
Bouchard continued, “This is an exciting time as the entire American Steel industry is restructuring, and with Esmark’s long-standing history of excellence, we are anxious to continue to grow and we’re well positioned to come in and operate.”
Founded in 1901, United States Steel Corporation is a steel producer serving the automotive, construction, appliance, energy, containers, and packaging industries.
Prior to founding Esmark, Bouchard was Vice President-Commercial for U.S. Steel in Europe, residing in Kosice, Slovak Republic. He was a member of the executive team that U.S. Steel dispatched to Kosice after having acquired the Slovakian National Steel Company (VSZ).
Bouchard was widely credited with the successful commercial restructuring, implementation, and subsequent growth strategy of the company's European sales, marketing, strategic planning, and customer service initiatives, and was ultimately responsible for the company's commercial operations in 42 countries. The Kosice operation became the most profitable steel asset owned by U.S. Steel at that time.
Esmark Steel Group, a wholly owned subsidiary of Esmark, Inc., is one of the United States’ leading processors and distributors of value-added flat-rolled steel and the third-largest U.S. producer of tin plate steel. We offer the products, services and innovations to help our customers gain and sustain the competitive edge in their industries.
More About Mr. Bouchard:
Bouchard is the Founder, Chairman, and Chief Executive Officer of Esmark Inc. and its predecessor and controlling shareholder, the Bouchard Group, which was formed in 1995 with an initial $500 investment and is still 100 percent privately owned by Bouchard. Over the years, the Bouchard Group has grown and evolved into a diversified VC Investment Holding Company with strategic assets engaged in the Industrial, Energy, Technology, Real Estate, Commodities industries, and Youth Sports and Development.
Esmark and the Bouchard Group's roots are firmly planted in the steel industry. In 2003, the company acquired two Chicago area steel services companies, Electric Coating Technologies and Sun Steel. The acquisitions served as the genesis for Bouchard to found and bring the legendary Fortune 50 Esmark name and brand back to life when he formed the new Esmark Inc. II in 2003 to focus on steel company acquisitions. Bouchard subsequently transferred his Bouchard Group steel assets and capitalized the new Esmark II in 2004.
In 2007, he and his management team successfully completed the first hostile tender/reverse merger in the history of the United States with the merger of Wheeling Pittsburgh Steel Corporation (formerly NASDAQ: WPSC) and Esmark II. Bouchard served as Chairman and Chief Executive Officer of the iconic Wheeling-Pittsburgh Steel Corporation in 2006 before completing the merger with Esmark in 2007. He then built Esmark II into a publicly traded (formerly NASDAQ: ESMK), $3 billion company before it was ultimately sold to OAO Severstal for $1.3 billion in August 2008.
Bouchard, through the Bouchard Group, later repurchased the Esmark name, trademark, and intellectual property from OAO Severstal and brought the Esmark name and respective brand back to life for a third time when he founded Esmark Inc. III in October of 2008 with no revenue and one employee. The Bouchard Group is Esmark's III controlling shareholder. Esmark III is one of the nation's fastest growing companies with assets in excess of $200 million. With its diverse portfolio of companies, Esmark III generates more than $500 million in revenue annually.
During his 30-year career, Bouchard has served on the Board of Directors of a number steel industry organizations and companies, including the American Iron and Steel Institute (AISI) in Washington, D.C. He also formerly served on the C.D.E. committee for Eurofer in Brussels, Belgium, and the Board of Directors for Wheeling-Nisshan Steel Corporation and Ohio Coatings Company.
In addition to serving as Chairman of the Board and CEO of Esmark Inc., Esmark Steel Group, Inc., and the Bouchard Group, he is Co-Chairman of Ohio Coatings Company (OCC) in Yorkville, Ohio. Bouchard also currently serves as a member of the Board of Trustees at Loyola University-Chicago and Robert Morris University. Bouchard is a Dartmouth University Tuck School of Business Entrepreneurial Management Instructor. As well, he is on the Board of Directors for several Pittsburgh-based organizations including FC Pittsburgh Soccer Club, the Imani Christian Academy, the Quaker Valley Hockey Association, and the City of Champions for Haiti humanitarian group.
Bouchard is also the Chairman and majority owner of Johnstown Sports Partners LLC and majority owner of the NAHL's Johnstown Tomahawks Hockey Team in Johnstown, PA.
Bouchard is the recipient of numerous industry and philanthropic awards for his accomplishments and contributions. In 2005, he was nominated and named as an Illinois Finalist of the prestigious Ernst & Young Entrepreneur of the Year Award. In March 2006, the Association of Steel Distributors bestowed their highest honor on him as "Steel Man of the Year." In 2007, he was inducted into the Hinsdale Central High School Hall of Fame, the youngest inductee in the history of the school. He is a recipient of the Hinsdale Central, James Carmanani Award. Bouchard was also honored by Loyola University as the 2007-08 recipient of the Chicago Damen Award for distinguished alumni. And in 2010, he was named a Paul Harris Fellow by Rotary International for his humanitarian relief efforts during the aftermath of the earthquake in Haiti. In 2012, Bouchard was named Sewickley, Pennsylvania's "Man of the Year" for his ongoing support of multiple children's charities, youth sports and development programs, and other humanitarian organizations throughout Western Pennsylvania and Pittsburgh's inner city. Also in 2012, Bouchard was named a finalist for "CEO of the Year" by global publishing concern Platts International and subsidiary Steel Business Briefing for his years of leadership, vision, and innovation in the steel industry. He is a part of the Pittsburgh City of Champions Hall of Fame and the Quaker Valley Hall of Fame.
James P. Bouchard family, along with the Esmark family of companies, continue to be tireless supporters of a wide range of educational, family health and wellness, youth sports and recreation programs in Pennsylvania, Illinois, and in Haiti including the Helen E. Bouchard Scholarship Award (totaling $500,000 to 75 recipients), with donations totaling more than $10 million since 2003.
About Esmark, Inc.
Esmark, Inc. is a diversified, privately-held family company with a portfolio of industrial companies with strong roots in the steel industry. Over the years, Esmark has diversified its interests and operations into a number of businesses engaged in the industrial and commodity sectors. Esmark (a former publicly traded company on NASDAQ: ESMK) has focused on several key industries including steel services, oil and gas exploration, aviation, real estate, professional services, technology and youth sports development. The company is also an active corporate citizen in the communities it serves, having committed more than $10 million in philanthropic support of a wide range of humanitarian, education, family wellness and youth sports programs in Pennsylvania, Illinois and internationally. www.esmark.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230814019728/en/
Contact information
Katie Regan
Director of Communications
Esmark, Inc.
Katie.regan@esmark.com
(708) 898-5550
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
